Regeneron convinces PTAB to review Novartis syringe patent

The US Patent Trial and Appeal Board (PTAB) has granted a review of a Novartis syringe patent following a challenge from biotech giant Regeneron.

Already registered?

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

Big Pharma

PTAB grants IPR of Regeneron Eylea patents

11 November 2021 The US Patent Trial and Appeal Board will review the validity of two Regeneron Pharmaceuticals patents related to its Eylea (aflibercept) medication.

Americas

Court dismisses Regeneron’s antitrust countersuit against Novartis

3 February 2022 Novartis escaped an antitrust countersuit brought by Regeneron earlier this week, with a New York court dismissing the suit which had been filed in response to Novartis’ patent complaint.

More on this story

Big Pharma

PTAB grants IPR of Regeneron Eylea patents

11 November 2021 The US Patent Trial and Appeal Board will review the validity of two Regeneron Pharmaceuticals patents related to its Eylea (aflibercept) medication.

Americas

Court dismisses Regeneron’s antitrust countersuit against Novartis

More on this story

Big Pharma

PTAB grants IPR of Regeneron Eylea patents

11 November 2021 The US Patent Trial and Appeal Board will review the validity of two Regeneron Pharmaceuticals patents related to its Eylea (aflibercept) medication.

Americas

Court dismisses Regeneron’s antitrust countersuit against Novartis